Schedule of Contract Assets and Contract Liabilities

Total contract assets at September 30, 2024 were as follows:


(In thousands)	Contract Assets
Contract assets at December 31, 2023	$	706
Additions		6,344
Transferred to receivables, net		(4,081	)
Contract assets at September 30, 2024	$	2,969

Total contract liabilities at September 30, 2024 were as follows:


(In thousands)	Contract Liabilities
Contract liabilities at December 31, 2023	$	4,775
Additions		34
Amounts recognized into revenue		(2,470	)
Contract liabilities at September 30, 2024	$	2,339

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2024 and 2023, the Company recorded product sales, net, as follows:


	Three Months Ended September 30,				Nine Months Ended September 30,
(In thousands)	2024		2023		2024		2023
VIVITROL	$	113,650	$	99,305	$	323,182	$	298,035
ARISTADA and ARISTADA INITIO		84,652		81,834		249,571		244,320
LYBALVI		74,697		50,683		203,055		135,671
Total product sales, net	$	272,999	$	231,822	$	775,808	$	678,026

Schedule of Disaggregation of Revenues

During the three and nine months ended September 30, 2024 and 2023, the Company recorded manufacturing and royalty revenues from its collaboration arrangements as follows:


	Three Months Ended September 30, 2024						Nine Months Ended September 30, 2024
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total		Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	58,448	$	58,448	$	—	$	199,860	$	199,860
VUMERITY		8,753		23,821		32,574		30,740		68,322		99,062
Other		7,194		6,928		14,122		35,517		17,396		52,913
	$	15,947	$	89,197	$	105,144	$	66,257	$	285,578	$	351,835


	Three Months Ended September 30, 2023						Nine Months Ended September 30, 2023
(In thousands)	Manufacturing Revenue		Royalty Revenue		Total		Manufacturing Revenue		Royalty Revenue		Total
Long-acting INVEGA products(1)	$	—	$	76,109	$	76,109	$	—	$	410,910	$	410,910
VUMERITY		9,733		24,828		34,561		32,751		62,979		95,730
Other		30,889		7,554		38,443		78,209		23,039		101,248
	$	40,622	$	108,491	$	149,113	$	110,960	$	496,928	$	607,888

(1)

“long-acting INVEGA products”: INVEGA SUSTENNA/XEPLION (paliperidone palmitate), INVEGA TRINZA/TREVICTA (paliperidone palmitate) and INVEGA HAFYERA/BYANNLI (paliperidone palmitate).